H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $5.00 price target on Invivyd Inc. (NASDAQ: IVVD).

The analyst commented: "Invivyd announced positive full Phase 1/2 data on June 26 for VYD2311, a next-generation monoclonal antibody (mAb) designed for both prevention and treatment of COVID-19, with long half-life, favorable safety, and broad route-of-administration flexibility. The data showed VYD2311 was well tolerated across intravenous (IV), intramuscular (IM), an subcutaneous (SC), with no serious adverse events and a half-life of up to 76 days for IM dosing. We believe these results position VYD2311 as a potential best-in-class prophylactic and treatment option with broad utility, especially via IM administration. Furthermore, with a Type C FDA meeting scheduled for early 3Q25 and discussions planned around registrational next steps, we view today’s update as a meaningful de-risking event for the platform. We reiterate our Buy rating and $5 price target on IVVD, and believe this program could emerge as a core value driver over the next 12 months."

For an analyst ratings summary and ratings history on Invivyd Inc. click here. For more ratings news on Invivyd Inc. click here.

Shares of Invivyd Inc. closed at $0.80 yesterday.

You May Also Be Interested In